Skip to main content

Table 6 Clinical features associated with biological DMARD use

From: Rheumatoid artrhitis treatment in Brazil: data from a large real-life multicenter study

Clinical featureaN(%)bOdds ratio for bDMARD use (95% CI)
High-titer rheumatoid factorc616 (56.1)1.45 (1.12–1.86)
Interstitial pneumoniad42 (3.8)1.84 (0.99–3.42)
Erosive diseasee602 (54.9)1.47 (1.14–1.89)
Cutaneous vasculitis13 (1.2)4.12 (1.26–13.47)
Subcutaneous nodules92 (8.3)1.73 (1.13–2.66)
  1. a Groups of patients with and without each feature were compared (binary logistic regression); p < 0.05 for all comparisons. b Total numbers and percentage of patients with the clinical feature among all those assessed for that condition. c Defined as at least 3 times the upper limit of normality d Defined by findings suggestive of interstitial X-ray disease: ground-glass opacities, fibrosis compatible lesions (honeycombing, traction bronchiectasis / bronchiolectasis, irregular interlobular septal thickening, and irregular interfaces) e Defined as at least 3 erosions in some specified joints (see methodology)